23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Nuvation Bio Inc. › 2025-2026

Nuvation Bio Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Nuvation Bio Inc.’s Form 8-K, filed May 27, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 194Asset managers, any item
  • 969Fund votes
  • May 21, 2026Meeting date

Results at a glance

Meeting of May 21, 2026: 4 items on Nuvation Bio Inc.’s Form 8-K, filed May 27, 2026: 2 elected · 2 approved.

Dissent

Notable dissent: 1 director (16.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2024-2025 2025-2026

Explore Nuvation Bio Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Nuvation Bio Inc.

These tallies are Nuvation Bio Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 27, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Nuvation Bio Inc. — official shareholder meeting results, meeting held May 21, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Robert B. Bazemore, Jr. 197,674,280---- 37,655,08255,602,434 84%Elected—
Elect Director: Robert Mashal, M.D. 216,772,840---- 18,556,52255,602,434 92%Elected—
2. Ratification of Independent Registered Public Accounting Firm 290,273,104413,176245,516 --0 99.9%Approved—
3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement 230,050,6444,950,024328,694 --55,602,434 98%Approved—

Source: Nuvation Bio Inc., Form 8-K, filed with the SEC on May 27, 2026 — read the filing on EDGAR.

How asset managers voted at the Nuvation Bio Inc. 2025-2026 meeting

194 asset managers disclosed a vote on at least one Nuvation Bio Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Robert B. Bazemore, Jr.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%WITHHELD
FOR: 197,674,280WITHHELD: 37,655,082
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Election of Directors: Robert Bazemore

Nuvation Bio Inc.’s own tally for this item (“Elect Director: Robert B. Bazemore, Jr.”): 197,674,280 for, 37,655,082 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 84% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 47,594,110 for, 13,634,955 withheld, 100,098 abstained.

FORWITHHOLD
FOR: 47,594,110ABSTAIN: 100,098WITHHOLD: 13,634,955
Largest asset managers voting on “Election of Directors: Robert Bazemore” at Nuvation Bio Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity23,708,7910 04,990,567Mixed
Vanguard13,681,2170 20,3659,611For
BlackRock7,249,1580 00For
American Century00 02,196,254Withhold
Charles Schwab00 01,963,390Withhold
TIAA00 01,186,668Withhold
State Street5730 0611,295Withhold
Equitable347,4520 0148,580Mixed
TANAKA FUNDS INC485,0000 00For
T. Rowe Price446,0820 00For
AIG/SunAmerica00 0394,982Withhold
Tema ETF Trust390,1950 00For
QUANTITATIVE MASTER SERIES LLC375,0870 00For
SEI00 0340,055Withhold
Dimensional00 0298,894Withhold
ALPS ETF Trust00 0287,737Withhold
Lincoln Financial00 0282,091Withhold
Invesco196,6720 00For
Brighthouse77,5740 072,553Mixed
BUFFALO FUNDS147,2210 00For
SEI Exchange Traded Funds00 0135,730Withhold
Northern Trust00 0119,420Withhold
Global X00 0112,780Withhold
Bridge Builder Trust103,1580 00For
MASTER INVESTMENT PORTFOLIO95,1610 00For

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

Elect Director: Robert Mashal, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 6 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 216,772,840WITHHELD: 18,556,522
Details: description as filed, official tally, votes by 54 asset managers

Description as filed by funds: Election of Directors: Robert Mashal, M.D.

Nuvation Bio Inc.’s own tally for this item (“Elect Director: Robert Mashal, M.D.”): 216,772,840 for, 18,556,522 withheld, per its Form 8-K filed May 27, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The individuals listed below were elected at the Annual Meeting to serve as directors of the Company until the Company's 2029 annual meeting of stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 54 asset managers below reported 56,141,835 for, 5,109,663 withheld, 77,665 abstained.

FOR
FOR: 56,141,835ABSTAIN: 77,665WITHHOLD: 5,109,663
Largest asset managers voting on “Election of Directors: Robert Mashal, M.D.” at Nuvation Bio Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity28,699,3580 00For
Vanguard13,711,1640 290For
BlackRock7,249,1580 00For
American Century00 02,196,254Withhold
Charles Schwab1,963,3900 00For
TIAA00 01,186,668Withhold
State Street611,3660 0502For
Equitable347,4520 0148,580Mixed
TANAKA FUNDS INC485,0000 00For
T. Rowe Price446,0820 00For
AIG/SunAmerica00 0394,982Withhold
Tema ETF Trust390,1950 00For
QUANTITATIVE MASTER SERIES LLC375,0870 00For
SEI340,0550 00For
Dimensional00 0298,894Withhold
ALPS ETF Trust00 0287,737Withhold
Lincoln Financial164,6000 0117,491Mixed
Invesco196,6720 00For
Brighthouse77,5740 072,553Mixed
BUFFALO FUNDS147,2210 00For
SEI Exchange Traded Funds135,7300 00For
Northern Trust119,4200 00For
Global X112,7800 00For
Bridge Builder Trust103,1580 00For
MASTER INVESTMENT PORTFOLIO95,1610 00For

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 9 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 230,050,644AGAINST: 4,950,024
Details: description as filed, official tally, votes by 194 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

Nuvation Bio Inc.’s own tally for this item (“3. To approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement”): 230,050,644 for, 4,950,024 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 55 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at Nuvation Bio Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity28,699,3580 00For
Vanguard13,711,1894 00For
BlackRock7,249,1580 00For
American Century02,196,254 00Against
Charles Schwab1,963,3900 00For
TIAA1,186,6680 00For
State Street611,84424 00For
Equitable496,0320 00For
TANAKA FUNDS INC485,0000 00For
T. Rowe Price446,0820 00For
AIG/SunAmerica394,9820 00For
Tema ETF Trust390,1950 00For
QUANTITATIVE MASTER SERIES LLC375,0870 00For
SEI340,0550 00For
Dimensional298,8940 00For
ALPS ETF Trust287,7370 00For
Lincoln Financial282,0910 00For
Invesco0196,672 00Against
Brighthouse150,1270 00For
BUFFALO FUNDS147,2210 00For
SEI Exchange Traded Funds135,7300 00For
Northern Trust119,4200 00For
Global X112,7800 00For
HUSSMAN INVESTMENT TRUST00 105,0000Abstain
Bridge Builder Trust103,1580 00For

Fund voting reports, all 55 managers: 58,901,365 for, 2,427,798 against, 105,000 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 158 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at Nuvation Bio Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity47,104,0030 00For
Decheng Capital LLC25,954,4390 00For
Omega Fund Management, LLC8,081,0890 00For
Laurion Capital Management LP7,768,2890 00For
BlackRock6,653,11541,646 00For
GEODE CAPITAL MANAGEMENT, LLC5,844,4980 00For
State Street3,333,6896,283 00For
Redmile Group, LLC3,153,2560 00For
Duquesne Family Office LLC2,628,2260 00For
American Century02,412,323 00Against
Charles Schwab1,966,7710 00For
Vanguard1,948,9920 00For
ABRAMS CAPITAL MANAGEMENT, L.P.1,270,5040 00For
Nuveen1,233,8250 00For
Northern Trust1,168,19219,057 00For
T. Rowe Price1,146,9130 00For
Two Sigma894,7630 00For
ALGERT GLOBAL LLC664,7880 00For
Connor, Clark & Lunn Investment Management Ltd.638,1850 00For
Beacon Pointe Advisors, LLC585,0510 00For
SEI558,0930 00For
Palo Alto Investors LP508,8460 00For
Wellington442,6000 00For
SILVERCREST ASSET MANAGEMENT GROUP LLC428,8480 00For
AQR419,6440 00For

Institutional-manager reports, all 158 managers: 128,296,993 for, 3,658,955 against, 45,962 abstained, 550 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Independent Registered Public Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 290,273,104AGAINST: 413,176
Details: description as filed, official tally, votes by 55 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Nuvation Bio Inc.’s own tally for this item (“2. Ratification of Independent Registered Public Accounting Firm”): 290,273,104 for, 413,176 against — passed, per its Form 8-K filed May 27, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 55 asset managers below reported 61,334,163 for.

FOR
FOR: 61,334,163
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCA” at Nuvation Bio Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity28,699,3580 00For
Vanguard13,711,1930 00For
BlackRock7,249,1580 00For
American Century2,196,2540 00For
Charles Schwab1,963,3900 00For
TIAA1,186,6680 00For
State Street611,8680 00For
Equitable496,0320 00For
TANAKA FUNDS INC485,0000 00For
T. Rowe Price446,0820 00For
AIG/SunAmerica394,9820 00For
Tema ETF Trust390,1950 00For
QUANTITATIVE MASTER SERIES LLC375,0870 00For
SEI340,0550 00For
Dimensional298,8940 00For
ALPS ETF Trust287,7370 00For
Lincoln Financial282,0910 00For
Invesco196,6720 00For
Brighthouse150,1270 00For
BUFFALO FUNDS147,2210 00For
SEI Exchange Traded Funds135,7300 00For
Northern Trust119,4200 00For
Global X112,7800 00For
Bridge Builder Trust103,1580 00For
MASTER INVESTMENT PORTFOLIO95,1610 00For

Showing the 25 largest of 55 asset managers. All 55 are in the interactive database (link above).

Largest Nuvation Bio Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 346,503,675 shares outstanding at the time of that meeting.

Fund voting reports: top Nuvation Bio Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 8.28%
2Vanguard 3.96%
3BlackRock 2.09%
4American Century 0.63%
5Charles Schwab 0.57%
6TIAA 0.34%
7State Street 0.18%
8Equitable 0.14%
9TANAKA FUNDS INC 0.14%
10T. Rowe Price 0.13%
Institutional-manager reports: top Nuvation Bio Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 13.59%
2Decheng Capital LLC 7.49%
3Omega Fund Management, LLC 2.33%
4Laurion Capital Management LP 2.24%
5BlackRock 1.93%
6GEODE CAPITAL MANAGEMENT, LLC 1.69%
7State Street 0.96%
8Redmile Group, LLC 0.91%
9Duquesne Family Office LLC 0.76%
10American Century 0.70%

Reported Nuvation Bio Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Nuvation Bio Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
David Hung, M.D.59,281,054 17.11%Proxy statement (DEF 14A), proxy filed April 10, 2026
FMR (Fidelity)51,989,593 15.00%Form 13F, quarter ended March 31, 2026
Entities affiliated with FMR LLC50,599,225 14.60%Proxy statement (DEF 14A), proxy filed April 10, 2026
Entities affiliated with Decheng Anbio Limited25,954,439 7.49%Proxy statement (DEF 14A), proxy filed April 10, 2026
Min Cui, Ph.D.25,954,439 7.49%Proxy statement (DEF 14A), proxy filed April 10, 2026
BlackRock25,100,374 7.24%Form 13F, quarter ended March 31, 2026
Vanguard Group15,555,606 4.49%Form 13F, quarter ended March 31, 2026
State Street6,784,927 1.96%Form 13F, quarter ended March 31, 2026
Geode Capital5,863,654 1.69%Form 13F, quarter ended March 31, 2026
Two Sigma2,684,089 0.77%Form 13F, quarter ended March 31, 2026

Percentages above are of 346,503,675 shares outstanding, as reported by Nuvation Bio Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Nuvation Bio Inc.'s shareholder meeting held May 21, 2026, in the 2025-2026 proxy season, 194 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 969 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — Nuvation Bio Inc.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Nuvation Bio Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 27, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nuvation Bio Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Nuvation Bio Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Nuvation Bio (NUVB) 2026 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/nuvation-bio-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.